Psychedelic-Assisted Psychotherapy for PTSD: Theory, Technique and Context
Image For Activity Cover
Expires on Jun 30, 2025
Credit Offered
0.75 CME Credit
0.75 COP Credit

Available: 06/30/2022 - 06/30/2025


There is no cost to participate in this activity or to earn CME credit. APA is making this activity available to its members as a benefit of APA membership. For ABPN diplomates, access to this program was supported through funding from the American Board of Psychiatry and Neurology (ABPN).

Psychedelics have long been employed by traditional healers to promote physical and mental recovery. The US Food and Drug Administration recently granted MDMA and psilocybin Breakthrough Therapy designation to accelerate study of their efficacy in psychiatric disorders while ketamine clinics multiply apace. Less obvious is the role which psychotherapy plays in the application and effectiveness of these compounds. This panel, designed to engage researchers, clinicians and policy makers, features Robert Koffman, M.D., CAPT, USN (Ret), first Senior Consultant for Integrative Medicine & Behavioral Health at the National Intrepid Center of Excellence, Mark Bates, PhD, LtCol, USAF (Ret), former branch chief, Psychological Health Promotion, DoD Psychological Health Center of Excellence, Rachel Yehuda, PhD, Director, Center for Psychedelic Psychotherapy and Trauma at the Icahn School of Medicine, Mount Sinai, and Harold Kudler, M.D., past Mental Health policy lead, U.S. Department of Veterans Affairs, who will review the pharmacological and psychological evidence base for psychedelic-assisted psychotherapy for PTSD, describe its clinical application and consider the role which altered states (sweat lodges, Mesmerism, hypnosis, sodium amytal and psychedelics) have played over the centuries in clinical and cultural efforts to transcend psychological trauma.

Learning Objectives

  • Identify the leading forms of psychedelic-assisted psychotherapy currently under study and describe their technical application.
  • Assess the evidence for the relative contributions of biological and psychological aspects of psychedelic-assisted psychotherapy for PTSD.
  • Assess the role which psychedelic-assisted psychotherapy may play within your own theoretical approach to psychological trauma and your clinical practice.

Target Audience

Psychiatrists, Residents/Fellows, Medical Students, non-psychiatrist physicians, other mental health professionals

Estimated Time to Complete

Estimated Duration: 45 minutes
Begin Date: June 30, 2022
End Date: June 30, 2025

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the completion date and hours earned. 

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The APA designates this enduring CME activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Program Presenters

  • Harold Kudler, Duke University. Reports no financial relationships with commercial interests.
  • Robert Kauffman, Reports no financial relationships with commercial interests.
  • Mark Bates, Reports no financial relationships with commercial interests.
  • Rachel Yehuda, PhD, Reports no financial relationships with commercial interests.

Program Planners

  • Ebony Harris, Assistant Director, Assistant Director, Online Learning at APA. Reports no financial relationships with commercial interests.
  • Katie Putnam, Manager, Member Development at APA. Reports no financial relationships with commercial interests.

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.

Technical Requirements

This internet-based CME activity is best experienced using any of the following:

  • The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
  • Internet Explorer 11+

This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

  • Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
  • Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
  • Internet Connection: 1 Mbps or higher

Minimum Requirements:

  • Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
  • Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content

For assistance: Contact for questions about this activity | Contact for technical assistance

Powered By